The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Open accessAbstract
BACKGROUND: BRAF V600 mutations occur in various nonmelanoma cancers. We undertook a histology-independent phase 2 "basket" study of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers. METHODS: We enrolled patients in six prespecified cancer cohorts; patients with all other tumor types were enrolled in a seventh cohort. A total of 122 patients with BRAF V600 mutation-positive cancer were treated, including 27 patients with colorectal cancer who received vemurafenib and cetuximab. The primary end point was the response rate; secondary end points included progression-free and overall survival. RESULTS: In the cohort with non-small-cell lung cancer, the response rate was 42% (95% confidence interval [CI], 20 to 67) and median progression-free survival was 7.3 months (95% CI, 3.5 to 10.8). In the cohort with Erdheim-Chester disease or Langerhans'-cell histiocytosis, the response rate was 43% (95% CI, 18 to 71); the median treatment duration was 5.9 months (range, 0.6 to 18.6), and no patients had disease progression during therapy. There were anecdotal responses among patients with pleomorphic xanthoastrocytoma, anaplastic thyroid cancer, cholangiocarcinoma, salivary-duct cancer, ovarian cancer, and clear-cell sarcoma and among patients with colorectal cancer who received vemurafenib and cetuximab. Safety was similar to that in prior studies of vemurafenib for melanoma. CONCLUSIONS: BRAF V600 appears to be a targetable oncogene in some, but not all, nonmelanoma cancers. Preliminary vemurafenib activity was observed in non-small-cell lung cancer and in Erdheim-Chester disease and Langerhans'-cell histiocytosis. The histologic context is an important determinant of response in BRAF V600-mutated cancers. (Funded by F. Hoffmann-La Roche/Genentech; ClinicalTrials.gov number, NCT01524978.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Indeed, in BRAFV600 colorectal cancer, targeting EGFR—the RTK thought to be the primary driver of feedback reactivation from preclinical studies—in combination with BRAF inhibition, has led to an improvement in clinical efficacy (34–39).”
From Vertical Pathway Inhibition Overcomes Adaptive Feedback Resistance to KRASG12C Inhibition (2020) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BRAF inhibitors have proven ineffective as single agents due to adaptive feedback re-activation of the MAPK and other signaling pathways [5–13, 38].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“BRAF inhibitor monotherapy is a promising treatment of many cancers, including melanoma and NSCLC; however, BRAF inhibitor efficacy in colorectal cancer patients with BRAF V600E mutations is limited (21).”
From Cetuximab Enhances the Efficacy of MRTX1133, a Novel KRASG12DInhibitor, in Colorectal Cancer Treatment (2023) · cites this paper as [21]
The cited source says what the claim attributes to it.
In the citing paper
“In contrast with other BRAFV600E tumors (i.e. melanoma), BRAFV600E-targeted therapy (like vemurafenib) has proven largely ineffective in CRC, with response rates <5% as single agents [5, 6].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [6]
In the citing paper
“However, in another clinical study, CRC patients did not benefit from vemurafenib monotherapy and/or cetuximab [161].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [161]
In the citing paper
“However, a multicentric clinical study containing 27 CRC patients showed that vemurafenib alone or with cetuximab did not benefit CRC patients [99].”
From Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies (2021) · cites this paper as [99]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Self-citationMutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
The cancer genome atlas pan-cancer analysis project
The Cancer Genome Atlas Research Network, Weinstein, J. N., Collisson, E. A., Mills, G. B., Shaw, K. R. M., Ozenberger, B. A., Ellrott, K., Shmulevich, I., Sander, C., & Stuart, J. M. (2013) · Nature Genetics · doi:10.1038/ng.2764 · Cited by 9,092
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
Bang, Y.-J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61121-x · Cited by 7,302
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
Self-citationThe Somatic Genomic Landscape of Glioblastoma
Brennan, C. W., Verhaak, R. G. W., McKenna, A., Campos, B., Noushmehr, H., Salama, S. R., Zheng, S., Chakravarty, D., Sanborn, J. Z., Berman, S. H., et al. (2013) · Cell · doi:10.1016/j.cell.2013.09.034 · Cited by 5,016
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
Shaw, A. T., Kim, D.-W., Nakagawa, K., Seto, T., Crinó, L., Ahn, M.-J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1214886 · Cited by 3,381
Flagged first, then by citations
Research works printed but not linked: 1
- Kimura ET, 2003, Cancer Res, 63, 1454
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Martinez, N., Khanna, O., & Farrell, C. J. (2020) · Chinese Clinical Oncology · doi:10.21037/cco-20-168 · Cited by 15
Nikanjam, M., Tinajero, J., Barkauskas, D. A., & Kurzrock, R. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0861 · Cited by 15
Precision Medicine for Colorectal Cancer with Liquid Biopsy and Immunotherapy
Nagayama, S., Low, S., Kiyotani, K., & Nakamura, Y. (2021) · Cancers · doi:10.3390/cancers13194803 · Cited by 16
Koeppel, F., Müller, E., Harlé, A., Guien, C., Sujobert, P., Trabelsi‐Grati, O., Kosmider, O., Miguet, L., Mauvieux, L., Cayre, A., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.08.047 · Cited by 15
Precision medicine in acute myeloid leukemia: Hope, hype or both?
Prasad, V. K., & Gale, R. P. (2016) · Leukemia Research · doi:10.1016/j.leukres.2016.07.011 · Cited by 15
Stratified Treatment in Lung Cancer
Michels, S. Y. F., & Wolf, J. (2016) · Oncology Research and Treatment · doi:10.1159/000453406 · Cited by 15
Self-citationAnaplastic gliomas in adults: an update
Izquierdo, C., Joubert, B., & Ducray, F. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000409 · Cited by 15
Using Genomics to Guide Treatment for Glioblastoma
Young, J. S., Prados, M. D., & Butowski, N. A. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0078 · Cited by 15
Dudnik, E., Bar, J., Peled, N., Bshara, E., Kuznetsov, T., Cohen, A. Y., Shochat, T., Nechushtan, H., Onn, A., Agbarya, A., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.03.007 · Cited by 16
Asano, J., & Hirakawa, A. (2020) · Pharmaceutical Statistics · doi:10.1002/pst.2049 · Cited by 15
Fung, A. S., Graham, D. M., Chen, E. X., Stockley, T. L., Zhang, T., Le, L. W., Albaba, H., Pisters, K. M. W., Bradbury, P. A., Trinkaus, M. A., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.05.021 · Cited by 15
BlackSheep: A Bioconductor and Bioconda Package for Differential Extreme Value Analysis
Blumenberg, L. M., Kawaler, E. A., Cornwell, M., Smith, S. A., Ruggles, K. V., & Fenyö, D. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00190 · Cited by 15
Specifying the True- and False-Positive Rates in Basket Trials
Cunanan, K. M., Iasonos, A. E., Shen, R., Hyman, D. M., Riely, G. J., Gönen, M., & Begg, C. B. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00181 · Cited by 15
Self-citationSpurgeon, L. C., Mitchell, C. L., Cook, N., & Conway, A. (2025) · British Journal of Cancer · doi:10.1038/s41416-025-03073-7 · Cited by 16
Advances in potential targeted therapies for Erdheim-Chester disease
Cavalli, G., Luca, G. D. D., & Dagna, L. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1285226 · Cited by 14
Li, S. D., Martial, A. M., Schrock, A. B., & Liu, J. J. (2017) · Experimental Hematology and Oncology · doi:10.1186/s40164-017-0089-y · Cited by 14
Prager, G., Unseld, M., Waneck, F., Mader, R., Wrba, F., Raderer, M., Fuereder, T., Staber, P., Jäger, U., Kieler, M., et al. (2019) · OncoTarget · doi:10.18632/oncotarget.26604 · Cited by 14
Tchekmedyian, V. (2021) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2021.05.011 · Cited by 16
Pharmacological agents targeting drug-tolerant persister cells in cancer
Chen, Y., Gowda, K., Amin, S., Schell, T. D., Sharma, A. K., & Robertson, G. P. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107163 · Cited by 16
Kemps, P. G., Woei-A-Jin, F. J. S. H., Schöffski, P., Tousseyn, T., Bempt, I. V., Meyer‐Wentrup, F. A. G., Dors, N., van Eijkelenburg, N. K. A., Vermeulen, M. A., Jazet, I. M., et al. (2024) · Blood Neoplasia · doi:10.1016/j.bneo.2024.100023 · Cited by 14
Tumor-Agnostic Genomic and Clinical Analysis of BRAF Fusions Identifies Actionable Targets
Chen, M. F., Yang, S., Tao, J. J., Desîlets, A., Diamond, E. L., Wilhelm, C., Rosen, E. Y., Gong, Y., Mullaney, K. A., Torrisi, J. M., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3981 · Cited by 14
Self-citationClinical Implementation of Novel Targeted Therapeutics in Advanced Breast Cancer
Chamberlin, M. D., Bernhardt, E. B., & Miller, T. W. (2016) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25590 · Cited by 14
Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers
Cabel, L., Fuerea, A. C., Lacroix, L., Baldini, C., Martin, P., Hollebecque, A., Postel-Vinay, S. C., Varga, A., Balheda, R., Gazzah, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.24188 · Cited by 14
Self-citationMoncur, J. T., Bartley, A. N., Bridge, J. A., Kamel‐Reid, S., Lazar, A. J., Lindeman, N. I., Long, T. A., Merker, J. D., Rai, A. J., Rimm, D. L., et al. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0396-cp · Cited by 14
Genomics-Enabled Precision Medicine for Cancer
Roos, A., & Byron, S. A. (2019) · Cancer treatment and research · doi:10.1007/978-3-030-16391-4_5 · Cited by 14
PIK3R1W624R Is an Actionable Mutation in High Grade Serous Ovarian Carcinoma
D’Ambrosio, C., Erriquez, J., Arigoni, M., Capellero, S., Mittica, G., Ghisoni, E., Borella, F., Katsaros, D., Privitera, S., Ribotta, M., et al. (2020) · Cells · doi:10.3390/cells9020442 · Cited by 15
Taghizadeh, H., Mader, R. M., Müllauer, L., Aust, S., Polterauer, S., KÖLBL, H., Seebacher, V., Grimm, C., Reinthaller, A., & Prager, G. W. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0904 · Cited by 14
Current and Future Systemic Therapies in Biliary Tract Cancer
Vogel, A., & Saborowski, A. L. (2021) · Visceral Medicine · doi:10.1159/000513969 · Cited by 14
Jiang, J., Gao, J., Wang, G., Lv, J., Chen, W., Ben, J., & Wang, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.688200 · Cited by 14
Wang, Z., Du, H., Chen, C., Liu, X., & Ke, N. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.801320 · Cited by 14
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15
Nakano, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316823 · Cited by 14
Investigation of patterns of nodal metastases in BRAF mutant lung cancer
McEvoy, S. H., Halpenny, D. F., Viteri, A., Hayes, S. A., Plodkowski, A. J., Riely, G. J., & Ginsberg, M. S. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.024 · Cited by 14
Universal Genomic Testing: The next step in oncological decision-making or a dead end street?
Holch, J. W., Metzeler, K. H., Jung, A., Riedmann, K., Jost, P. J., Weichert, W., Kirchner, T., Heinemann, V., & Westphalen, C. B. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.034 · Cited by 14
Network science in clinical trials: A patient-centered approach
Manem, V. S., Salgado, R., Aftimos, P. G., Sotiriou, C. P., & Haibe‐Kains, B. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.12.006 · Cited by 14
Distinctive Desmoplastic 3D Morphology Associated With BRAFV600E in Papillary Thyroid Cancers
Tarabichi, M., Antoniou, A., Pennec, S. L., Gacquer, D., Aubain, N. D. S., Craciun, L., Cielen, T., Laı̈os, I., Larsimont, D., Andry, G., et al. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02279 · Cited by 14
Kieler, M., Unseld, M., Bianconi, D., Waneck, F., Mader, R. M., Wrba, F., Fuereder, T., Marosi, C., Raderer, M., Staber, P. B., et al. (2019) · ESMO Open · doi:10.1136/esmoopen-2019-000538 · Cited by 14
Yee, L. M., McShane, L. M., Freidlin, B., Mooney, M., & Korn, E. L. (2019) · The Cancer Journal · doi:10.1097/ppo.0000000000000384 · Cited by 14
Cavalli, G., Dagna, L., Biavasco, R., Villa, A., Doglioni, C., Ferrero, E., & Ferrarini, M. (2020) · Journal of Leukocyte Biology · doi:10.1002/jlb.3mr0120-203rr · Cited by 14
New Genetic Technologies in Diagnosis and Treatment of Cancer of Unknown Primary
Krawczyk, P. A., Jassem, J., Wojas‐Krawczyk, K., Krzakowski, M. J., Dziadziuszko, R., & Olszewski, W. T. (2022) · Cancers · doi:10.3390/cancers14143429 · Cited by 13
A Patient With Lung Adenocarcinoma With BRAF Gene Fusion and Response to Vemurafenib
Zhu, Y., Wang, W., Xu, C., Zhuang, W., Du, K., Chen, G., Lv, T., & Song, Y. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.02.020 · Cited by 14
Histiocitosis de células de Langerhans. Avances en la patogenia y práctica clínica
Astigarraga, I., García‐Obregón, S., Pérez‐Martínez, A., Gutiérrez-Carrasco, I., Santa‐María, V., Iturrate, C. R.-V., Reggiori, M. L., Murciano, T., & Torrent, M. (2022) · Anales de Pediatría · doi:10.1016/j.anpedi.2022.05.002 · Cited by 13
Friedman, N., Weinstein‐Fudim, L., Mostinski, Y., Elia, J., Cohen, S., Steinberg, E., Frankenburg, S., Peretz, T., Eisenberg, G., Lotem, M., et al. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.abo0684 · Cited by 13
Translational research of new developments in targeted therapy of colorectal cancer
Yang, L., Atakhanova, N. E., Arellano, M. T. C., Mohamed, M. Y., Hani, T., Fahdil, A. A., Castillo-Acobo, R. Y., Juyal, A., Hussein, A. K., Amin, A. H., et al. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154888 · Cited by 14
Al-Wahaibi, L. H., Youssif, B. G. M., Abou‐Zied, H. A., Bräse, S., Brown, A. B., Tawfeek, H. N., & El‐Sheref, E. M. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00230j · Cited by 13
Strategies for treating the cold tumors of cholangiocarcinoma: core concepts and future directions
Zhang, G., Li, J., Li, G., Zhang, J., Yang, Z. P., Yang, L., Jiang, S., & Wang, J. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01460-7 · Cited by 14
Cross-omics strategies and personalised options for lung cancer immunotherapy
Yan, Y., Shen, S., Li, J., Su, L., Wang, B., Zhang, J., Lu, J., Luo, H., Han, P., Ke Cheng, X. U., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1471409 · Cited by 14
Sun, Z., Shi, M., Xia, J., Li, X., Chen, N., Wang, H., Gao, Z., Jia, J., Peng, Y., Ji, D., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010460 · Cited by 13
Genetics of Pancreatic Cancer and Its Implications on Therapy
Tatarian, T., & Winter, J. M. (2016) · Surgical Clinics of North America · doi:10.1016/j.suc.2016.07.014 · Cited by 14
A novel molecular diagnostics platform for somatic and germline precision oncology
Cabanillas, R., Diñeiro, M., Castillo, D., Pruneda, P., Penas, C., Cifuentes, G. Á., de Vicente, Á., Sánchez-Durán, N., Álvarez, R., Ordóñez, G. R., et al. (2017) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.291 · Cited by 13
Sensitization of HT29 colorectal cancer cells to vemurafenib in three‐dimensional collagen cultures
Kikuchi, K., & Hoshino, D. (2019) · Cell Biology International · doi:10.1002/cbin.11262 · Cited by 12
Molecular mechanism of acquired drug resistance in the EGFR‐TKI resistant cell line HCC827‐TR
Yu, T., Qian, X., Gong, T., Wang, J., & Zhong, D. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13342 · Cited by 13
Dong, D., Shen, G., Da, Y., Zhou, M., Yang, G., Yuan, M., & Chen, R. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0609 · Cited by 13
Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer
Abdayem, P., & Planchard, D. (2021) · European Respiratory Review · doi:10.1183/16000617.0294-2020 · Cited by 14
Lü, Y., Li, X., Zhao, K., Shi, Y., Deng, Z., Yao, W., & Wang, J. (2022) · Cells · doi:10.3390/cells11193088 · Cited by 13
Crickx, É., Bouaziz, J., Lorillon, G., de Menthon, M., Cordoliani, F., Bugnet, E., Bagot, M., Rybojad, M., Mourah, S., & Tazi, A. (2017) · Acta Dermato Venereologica · doi:10.2340/00015555-2674 · Cited by 13
Pierry, C., Caumont, C., Blanchard, É., Brochet, C., Dournes, G., Gros, A., Bandres, T., Verdon, S., Marty, M., Bégueret, H., et al. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2185-0 · Cited by 13
Abadal, K. B., Walsh, M. A., Yachnis, A. T., Tran, D. D., & Ghiaseddin, A. P. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00055 · Cited by 13
KUBOTA, N., Taniguchi, F., Nyuya, A., Umeda, Y., Mori, Y., Fujiwara, T., Tanioka, H., Tsuruta, A., Yamaguchi, Y., & Nagasaka, T. (2020) · Oncology Letters · doi:10.3892/ol.2020.11365 · Cited by 13
Tumor Type Agnostic Therapy Carrying BRAF Mutation: Case Reports and Review of Literature
Bernocchi, O., Sirico, M., Corona, S. P., Strina, C., Milani, M., Cappelletti, M. R., Ferrero, G., Ziglioli, N., Cervoni, V., Macchiavelli, A., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14020159 · Cited by 13
Odeniyide, P., Shahab, S., Dunn, E. A., Rhee, D. S., Jiang, L., Dome, J. S., Friedman, A. D., Argani, P., & Pratilas, C. A. (2020) · Molecular Case Studies · doi:10.1101/mcs.a004820 · Cited by 14
The role of polo‐like kinase 3 in the response of BRAF‐mutant cells to targeted anticancer therapies
Babagana, M., Kichina, J. V., Slabodkin, H., Johnson, S., Maslov, A., Brown, L., Attwood, K., Nikiforov, M. A., & Kandel, E. S. (2020) · Molecular Carcinogenesis · doi:10.1002/mc.23123 · Cited by 12
Is Personalized Medicine Here?
Carneiro, B. A., Costa, R. L. B., Taxter, T., Chandra, S., Chae, Y. K., Cristofanilli, M., & Giles, F. J. (2016) · PubMed · Cited by 12
Wang, H., Yu, Y., Wang, K., & Sun, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769807 · Cited by 12
Polk, J. B., Campbell, J., Drilon, A. E. D. C., Keating, P., & Cambrosio, A. (2023) · Social Science & Medicine · doi:10.1016/j.socscimed.2023.115789 · Cited by 12
Чойнзонов, Е. Л., Reshetov, I. V., Иванов, С. А., Polyakov, A. P., Кропотов, М. А., Mudunov, A. M., Викторович, П. В., Isaev, P. A., Ilyin, A. A., Beltsevich, D. G., et al. (2023) · Endocrine Surgery · doi:10.14341/serg12792 · Cited by 12
Daniells, L., Mozgunov, P., Bedding, A. W., & Jaki, T. (2023) · Statistics in Medicine · doi:10.1002/sim.9867 · Cited by 12
Ha, H., Lee, H. Y., Kim, J. H., Kim, D. Y., An, H. J., Bae, S., Park, H.-S., & Kang, J. H. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.128 · Cited by 14
Miguel, C. A.-D., Jiménez-Castro, J., Sanchez-Vegas, A., Díaz-López, S., & Chaves-Conde, M. (2024) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2024.104454 · Cited by 13
Chaudhary, R., Kumar, A., Singh, A., Agarwal, V., Rehman, M., Kaushik, A. S., Srivastava, S., Srivastava, S., & Mishra, V. (2025) · Disease-a-Month · doi:10.1016/j.disamonth.2024.101845 · Cited by 14
Targeted agents and combinations in ovarian cancer: where are we now?
McLachlan, J., Lima, J. P. D. S. N., Dumas, L., & Banerjee, S. N. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1162101 · Cited by 12
Subbiah, V., Hess, K. R., Khawaja, M. R., Wagner, M. J., Tang, C. Z., Naing, A., Fu, S., Jankú, F., Piha-Paul, S. A., Tsimberidou, A. M., et al. (2016) · Scientific Reports · doi:10.1038/srep35448 · Cited by 12
Self-citationSite-agnostic biomarker-guided oncology drug development
Jørgensen, J. T. (2019) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1702521 · Cited by 12
Broglio, K. R., Zhang, F., Yu, B., Marshall, J., Wang, F., Bennett, M., & Viele, K. (2021) · Statistics in Biopharmaceutical Research · doi:10.1080/19466315.2021.2008484 · Cited by 12
He, L., Ren, Y., Chen, H., Guinn, D., Parashar, D., Chen, C., Yuan, S. S., Korostyshevskiy, V. R., & Beckman, R. A. (2022) · Statistical Methods in Medical Research · doi:10.1177/09622802221091901 · Cited by 12
Encorafenib plus cetuximab for the treatment of BRAF-V600E-mutated metastatic colorectal cancer
Ros, J., Gonzalez, N. S., Baraibar, I., Salvà, F., Tabernero, J. M., & Élez, E. (2022) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848221110644 · Cited by 12
Self-citationGao, X., Hong, C., Xie, Y., & Zeng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1103147 · Cited by 12
Inflammation across tissues: can shared cell biology help design smarter trials?
Hosack, T., Thomas, T. R., Ravindran, R. P., Uhlig, H. H., Travis, S. P. L., & Buckley, C. D. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-01007-2 · Cited by 12
Creating Chemotherapeutic-Resistant Breast Cancer Cell Lines: Advances and Future Perspectives
Steding, C. E. (2016) · Future Oncology · doi:10.2217/fon-2016-0059 · Cited by 13
Targeting the serrated pathway of colorectal cancer with mutation in BRAF
Matos, P., Gonçalves, V., & Jordan, P. (2016) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2016.06.003 · Cited by 13
Basket trial approach capitalizes on the molecular mechanisms of tumors
Ornes, S. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1608277113 · Cited by 12
How the Lab is Changing Our View of Colorectal Cancer
Cremolini, C., & Pietrantonio, F. (2016) · Tumori Journal · doi:10.5301/tj.5000551 · Cited by 12
Erdheim-Chester disease, moving away from the orphan diseases: A case report
Stempel, J. M., Alvarez, J. G. B., Carpio, A. M., Mittal, V., & Dourado, C. M. (2016) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2016.11.013 · Cited by 12
Informing materials: drugs as tools for exploring cancer mechanisms and pathways
Vignola‐Gagné, É., Keating, P., & Cambrosio, A. (2017) · History & Philosophy of the Life Sciences · doi:10.1007/s40656-017-0135-4 · Cited by 12
Contribution of bladder cancer pathology assessment in planning clinical trials
Guo, C. C., Al‐Ahmadie, H. A., Flaig, T. W., & Kamat, A. M. (2018) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2018.01.001 · Cited by 12
Planchard, D., & Johnson, B. E. (2018) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0088-ed · Cited by 12
Lukas, R. V., & Merrell, R. T. (2018) · CNS Oncology · doi:10.2217/cns-2017-0032 · Cited by 12
Groisberg, R., Maymani, H., & Subbiah, V. (2018) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2018.1480898 · Cited by 12
Self-citationMEK Inhibition Induces Therapeutic Iodine Uptake in a Murine Model of Anaplastic Thyroid Cancer
ElMokh, O., Taelman, V. F., Radojewski, P., Roelli, M. A., Stooss, A., Dumont, R. A., Dettmer, M. S., Phillips, W. A., Walter, M. A., & Charles, R. (2018) · Journal of Nuclear Medicine · doi:10.2967/jnumed.118.216721 · Cited by 12
Heim, D., Montavon, G., Hufnagl, P., Müller, K., & Klauschen, F. (2018) · Genome Medicine · doi:10.1186/s13073-018-0591-9 · Cited by 12
Variant information systems for precision oncology
Starlinger, J., Pallarz, S., Ševa, J., Rieke, D. T., Sers, C., Keilholz, U., & Leser, U. (2018) · BMC Medical Informatics and Decision Making · doi:10.1186/s12911-018-0665-z · Cited by 12
Next-Generation Sequencing in 305 Consecutive Patients: Clinical Outcomes and Management Changes
Davis, W., Makar, G. S., Mehta, P., Zhu, G. G., Somer, R. A., Morrison, J., & Kubicek, G. J. (2019) · Journal of Oncology Practice · doi:10.1200/jop.19.00269 · Cited by 12
Piña, Y., Fusco, M. J., Macaulay, R. J. B., Walko, C. M., Peguero, E. N., Evernden, B. R., Smalley, K. S. M., & Forsyth, P. A. (2019) · Journal of Neurology · doi:10.1007/s00415-019-09575-8 · Cited by 12
Combing the Cancer Genome for Novel Kinase Drivers and New Therapeutic Targets
Torres‐Ayuso, P., & Brognard, J. (2019) · Cancers · doi:10.3390/cancers11121972 · Cited by 14
Baraibar, I., Ros, J., Mulet-Margalef, N., Salvà, F., Argilés, G., Martini, G., Cuadra‐Urteaga, J. L., Sardo, E., Ciardiello, D., Tabernero, J. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1782194 · Cited by 13
Self-citationDrug Development in Tissue-Agnostic Indications
du Rusquec, P., & Tourneau, C. L. (2021) · Cancers · doi:10.3390/cancers13112758 · Cited by 12
Rodriquenz, M. G., Ciardiello, D., Latiano, T. P., Maiorano, B. A., Martinelli, E., Silvestris, N., Ciardiello, F., & Maiello, E. (2022) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2022.103657 · Cited by 12
Genomic insights in gynecologic cancer
Roddy, E., & Chapman, J. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.001 · Cited by 12
Mitiushkina, N. V., Kholmatov, M. M., Venina, A. R., Tiurin, V. I., Yanus, G. A., Николаевна, С. Т., Yatsuk, O. S., Zaitseva, O. A., Ivantsov, A. O., Kuligina, E. S., et al. (2018) · Neoplasma · doi:10.4149/neo_2018_171225n843 · Cited by 11
Stover, E. H., Feltmate, C. M., Berkowitz, R. S., Lindeman, N. I., Matulonis, U. A., & Konstantinopoulos, P. A. (2018) · JCO Precision Oncology · doi:10.1200/po.18.00135 · Cited by 12
Metadata
- Authors
- Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., Gervais, R., Elez-Fernandez, M. E., Italiano, A., Hofheinz, R.-D., Hidalgo, M., Chan, E., Schuler, M., Lasserre, S. F., Makrutzki, M., Sirzen, F., Veronese, M. L., Tabernero, J., & Baselga, J.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- From Memorial Sloan Kettering Cancer Center, New York (D.M.H., E.L.D., J.B.); Vanderbilt University Medical Center, Nashville (I.P., E.C.); University of Texas M.D. Anderson Cancer Center, Houston (V.S.); Massachusetts General Hospital, Boston (J.E.F., N.S.R.); Royal Marsden Hospital, Sutton, Surrey, United Kingdom (I.C.); Centre Léon Bérard, Lyon (J.-Y.B.), Institut Gustave Roussy, Villejuif (A.H.), Centre François Baclesse, Centre Hospitalier Universitaire Côte de Nacre, Caen (R.G.), and Institut...
- F. Hoffmann-La Roche AG (CH)
- Universitat Autònoma de Barcelona (ES)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-08-20
- Volume
- 373
- Issue
- 8
- Pages
- 726-736
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4971773
- OpenAlex
- W1846586690
- Semantic Scholar
- abd7e5ae4940f84d6af08e479e67fa7e4788098c
- Cited by
- 1,764
- References
- 31
- Citations by year
- 2026: 55 · 2025: 102 · 2024: 115 · 2023: 122 · 2022: 143 · 2021: 189 · 2020: 210 · 2019: 192 · 2018: 192 · 2017: 241 · 2016: 169 · 2015: 30
- FWCI
- 91.52
- Type
- journal article
- Language
- en
- Update notices
- correction (2018-10-18)
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Funders
- F. Hoffmann-La Roche
- National Cancer Institute (P30CA008748)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- vemurafenib, BRAF V600 mutation, basket trials, non-small cell lung cancer, Erdheim-Chester disease, Langerhans cell histiocytosis, colorectal cancer, cetuximab, pleomorphic xanthoastrocytoma, anaplastic thyroid carcinoma, cholangiocarcinoma, ovarian cancer, clear cell sarcoma, targeted therapy
- MeSH terms
- Vemurafenib, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Indoles, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasms, Sulfonamides, Histiocytosis, Disease-Free Survival, Proto-Oncogene Proteins B-raf
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
